😽 natera

Better, together.

Natera Women's Health Family of Genetic Tests

Everything you need from a name you can trust.

For your patients, you demand precision and accuracy. For your practice, you need ease. With our Women's Health family of products, both are easily within reach.

From planning a family and prenatal testing to hereditary cancer screening, Natera offers high-quality genetic testing across the women's health spectrum.

Your unified solution for top-performing tests in women's health

> Panorama® Next-generation NIPT

> > Horizon™ Advanced carrier screening

> > > **Empower**[™] Hereditary cancer test

> > > > **Spectrum**[®] Preimplantation genetics

Vistara Single-gene NIPT

Anora[®] Miscarriage test (POC)



Born from a personal mission, Natera revolutionized prenatal testing by pioneering unique single-nucleotide polymorphism (SNP)-based cell-free DNA (cfDNA) technology.

Backed by scientific data and clinical evidence, Natera created the market's most accurate noninvasive prenatal test (NIPT).

With continued innovation, Natera has delivered a complete women's health portfolio and applied cfDNA expertise across organ health and oncology. In 2004, my sister gave birth to a son with Down syndrome. He passed away six days after birth. It was a devastating experience for our entire family. We wish we could have been better prepared.

I founded Natera because I believe all families deserve access to technologies that offer early detection of genetic disease.

We started with reproductive genetic screening, and now we're applying our expertise to early detection of cancer recurrence and renal transplant rejections.



Matthew Rabinowitz Founder of Natera

Stats at a glance 3M+ 10+ years of continued innovation peer-reviewed publications partnerships through constellation*

*Constellation provides lab partners the ability to develop their own SNP-based NIPT in-house with flexible partnership models



Pioneering technology powering the #1 noninvasive prenatal test on the market

Panorama noninvasive prenatal testing (NIPT) uses cell-free DNA (cfDNA) and unique SNP-based technology to deliver the most comprehensive, accurate, and reliable NIPT on the market.^{1–13}

Panorama can screen for the following conditions as early as nine weeks:

Whole-chromosome conditions

Optional conditions

- Trisomy 21, 18, 13
- Monosomy X
- Sex chromosome trisomies
- Triploidy


- 22q11.2 deletion syndrome
- Additional microdeletions
- Fetal sex



The 2020 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 226 recommends that **aneuploidy screening options**—**specifically including NIPT**—**be discussed with all pregnant patients**, regardless of maternal age or prior risk.¹⁴

Moreover, the organization endorses **NIPT as "the most sensitive and specific screening test for the common aneuploidies."**¹⁴

Only SNP-based NIPT provides three areas of differentiation



Accuracy and reliability

Unlike the counting methodology used by all other NIPTs on the market, only Panorama uses SNP-based technology to distinguish between maternal and fetal (placental) cfDNA.


Twins differentiation



"Cell-free DNA screening [NIPT] can be performed in twin gestations.

"... one laboratory method which uses SNP analysis reports zygosity as well as individual fetal fractions."

Continued innovation drives enhanced capabilities





The data is in: Panorama delivers greater accuracy and reliability

Panorama's technology surpasses the competitors', providing you and your patients with reliable prenatal insights.

Strong real-world performance - robust positive predictive values (PPVs), regardless of age¹⁵⁻¹⁸

Panorama clinical PPVs for trisomy 21









2 Highest-quality standards - lowest error rates among all NIPTs in published validation studies

Combined T21, T18, T13 false negative rates



3 Scientific leadership - more peer-reviewed publications and patients studied

Number of peer-reviewed publications (NIPT)



Patients studied

Fetal sex errors

>1.3 million
25,963
232,504
347,768
145,360
1,400
-

Comprehensive, actionable carrier screening—with an emphasis on ease

Horizon carrier screening leverages next-generation sequencing technology to give your patients comprehensive insights on their risk of passing on serious genetic conditions. Horizon uniquely combines actionable results with support resources tailored for your patients and practice.

Carriers are common, and family history is not a predictor

Family history: not a predictor

88%

of carriers of cystic fibrosis, spinal muscular atrophy, and fragile X syndrome have no known family history.¹⁹

Carrier frequency

1 in 9

people are carriers when screened with the Horizon 14 standard panel. $^{\rm 20}$

Combined incidence

1 in 634

babies born are affected by one of the conditions in the Horizon 14 standard panel.^{20,21}

ACOG says...

Carrier screening is no longer a "nice-to-have"; it's now best practice—regardless of ethnicity and screening strategy. **ACOG recommends carrier screening for all patients, either preconception or during pregnancy.**²²

Carrier screening facilitates informed decision-making and early preparation

PRECONCEPTION

- Get genetic counseling.
 - Pursue alternative reproductive options.

PREGNANCY

- Undergo diagnostic testing.
- Assemble an appropriate care team and specialist facility for delivery.
- Plan financially and prepare emotionally.

POST-DELIVERY

• Access early interventions, including FDA-approved treatment and clinical trials.

Leading-edge technology meets support for your patients and practice

Exceptional breadth and flexibilitythoughtfully designed panels screen up to 274 conditions.

Horizon 4 Pan-ethnic basic

CF, SMA, fragile X, DMD

Horizon 106 Comprehensive Jewish

Cystic fibrosis

Traditional genotyping tests

carriers detected by Horizon.²⁰

ACOG says...

"A number of expanded mutation

panels ... can be considered to

enhance sensitivity for carrier

detection, especially in non-

Caucasian ethnic groups."23

can miss up to 44% of

2

Horizon 14 Pan-ethnic standard includes hemoglobinopathies

Horizon 27 Pan-ethnic medium

Horizon 274 Pan-ethnic extended

Hemoglobinopathies

Traditional screening misses ~60% of patients Horizon identifies as at-risk.20

Spinal muscular atrophy



High detection rates - advanced technology detects more carriers.

"[A subset] of the general population ... will not be identified as being a carrier ... using [traditional methods]."23 CBC* and electrophoresis testing alone could miss 90% of alpha- and 6% of betahemoglobinopathy carriers detected by Horizon.20



ACOG says...

"A combination of laboratory tests may be required to provide the information necessary to counsel couples."23

*CBC = complete blood count

3 **Comprehensive support**—tools and services meet provider and patient needs. Browse a few of our offerings:

Ordering

Horizon/Panorama Combo Kit requires only one blood draw, requisition form, and kit.





The Patient Call-Out Program (PCOP) delivers results and provides interactive genetic education via **NEVA**,* available 24/7.

* Natera's Educational Virtual Assistant

Partner testing



Partner Auto-Enroll


streamlines your workflow for testing partners of patients with positive Horizon results.



Hereditary cancer testing, simplified

Empower is a genetic test for those who want to know more about their risk for developing cancer or why cancer might be common in their family. Empower includes genes associated with increased risk of hereditary cancers, with panel options to suit your preferred screening strategy.

Four panel options with up to 53 genes across eight common hereditary cancer types



Empower is delivered with clinical rigor

DEVELOPED IN PARTNERSHIP WITH BAYLOR **GENETICS**

- An expert curation team classifies variants according to American College of Medical Genetics (ACMG) guidelines.
- Baylor Genetics regularly contributes clinically significant variants to ClinVar public database for the benefit of patients and the medical community.

Natera offers support tools for busy providers

- Actionable reports to inform patient management based on the latest medical guidelines
- Testing for first-degree relatives of patients with a positive result at no additional charge (Visit natera.com/empower for more details.)

Natera's Educational Virtual Assistant



"Hi, I'm NEVA, and I have a few questions about your family history of cancer."

- Enables streamlined collection of family cancer history
- Supports an end-to-end virtual workflow for test orders

More-informed embryo selection, proven to boost IVF success

Spectrum helps you identify the healthiest embryos during an IVF cycle. This helps reduce time to pregnancy and improve your patients' chances for a successful pregnancy while decreasing the chance of miscarriage or of having a child with a genetic condition.

Spectrum preimplantation genetic testing (PGT) offers the following test types:



PGT-A (Aneuploidy) including haploidy, triploidy, and uniparental disomy (UPD)




PGT-M (Monogenic / single gene conditions)



PGT-SR (Structural Rearrangements) including translocations and inversions

Proven technology meets peace of mind and simplicity



Spectrum with Parental Support[™] is the only technology to confirm an embryo matches parental samples. It can also determine parental source of chromosomal abnormality.


Spectrum enables simultaneous PGT-M and PGT-A testing using a single embryo biopsy sample.

The Spectrum Advantage Program makes Spectrum available for only \$99 to couples who screen positive as carriers of a genetic condition using Natera's Horizon carrier screening.²⁵



The next innovation in NIPT technology

The most comprehensive prenatal single-gene screening test, Vistara screens cell-free DNA (cfDNA) for serious genetic conditions that affect quality of life that could benefit from early intervention, and that may have otherwise gone undetected.



Vistara provides a deeper level of clinically actionable information

Vistara screens for:	
25 conditions across 30 genes, including skeletal, cardiac, and neurological disorders	>99% sensitivity and specificity based on clinical validation published in <i>Nature Medicine</i> ²⁷
Conditions not reliably detected by existing modalities	Consider Vistara for: Image: Women who want to know as much as possible, noninvasively Image: Ultrasound anomalies
Conditions requiring significant changes to labor or delivery management and neonatal interventions or surgery	Family history of hereditary conditions Advanced paternal age ²⁸

Insights to guide next steps—from the most comprehensive miscarriage test

For more than a decade, Anora has been used to determine whether a chromosomal abnormality was the likely cause of a miscarriage.

Results can help explain why a miscarriage occurred and, possibly, whether your patient is at increased risk for a chromosomal abnormality in a future pregnancy. For many patients, this knowledge can help ease their emotional burden and inform reproductive decisions moving forward.

Anora miscarriage test can detect:



Aneuploidy and triploidy



Deletions and duplications >5 Mb and down to 1 Mb if clinically significant



Uniparental disomy (UPD)

SNP-based technology with Parental Support[™] delivers more

Anora uses sophisticated SNP-based microarray analysis combined with Natera's exclusive Parental Support technology to offer clear advantages over traditional products of conception (POC) testing methods.²⁹

Identifies parental origin of chromosomal abnormalities* to inform reproductive and post-pregnancy care

Detects partial and complete molar pregnancies, which require medical follow-up

Rules out maternal cell contamination (MCC) from a normal female fetal result

Provides a result >99% of the time, versus a 10%–40% chance of no results with karyotyping^{30,31}

Delivers results in about one week, versus two to five weeks for karyotyping

*When a parental blood or buccal sample is submitted.



NateraCore—simple, tailored resources to support you and your patients every step of the way

Natera Women's Health provides more than advanced tests; we make them intuitive and accessible. Through our NateraCore support resource, we deliver a selection of tools and services for every point in a patient's journey, whether remote or in-person.

Education	Access	Ordering	Results	Next steps
Patient-friendly materials and information sessions covering basic genetics and specific tests	Programs and price transparency—rooted in our commitment to provide affordable testing for all who can benefit	Flexible options based around your needs, including intuitive remote ordering	Clear, actionable reports served with time-saving tools and a side of expert guidance	Value-add services that go beyond the test to address what's next

A selection of our NateraCore offerings



Pre- and post-test genetic information sessions – access to board-certified genetic counselors, available to all providers and patients



Price Transparency Program (**PTP**)—personalized cost estimates and a self-pay cash alternative



Virtual testing – fully remote testing option combining online ordering with self-serve patient education and mobile phlebotomy



Flexible phlebotomy options-

via local Natera-approved lab or at-home mobile services; available in all states, at no cost to patients

Visit natera.com to learn more about how Natera innovations are advancing care for patients.

References

- 1 Nicolaides et al. Prenat Diagn. 2013;33(6):575-9.
- 2 Pergament et al. Obstet Gynecol. 2014;124(2 Pt 1):210-8.
- 3 Ryan et al. *Fetal Diagn Ther.* 2016;40(3):219-223.
- 4 Stokowski et al. Prenat Diagn. 2015;35(12):1243-6.
- 5 Jones et al. *Ultrasound Obstet Gynecol.* 2018;51(2):275-276.
 6 Palomaki et al. *Genet Med.* 2011;13(11):913-20.
- 7 Palomaki et al. *Genet Med.* 2012;14(3):296-305.
- 8 Porreco et al. Am J Obstet Gynecol. 2014;211:365.e1-12.
- 9 Mazloom et al. Prenat Diagn. 2013;33(6):591-7.
- 10 Sehnert et al. Clin Chem. 2011;57(7):1042-1049.
- 11 Bianchi et al. *Obstet Gynecol.* 2012;119(5):890-901. 12 Bianchi et al. *N Engl J Med.* 2014;370:799-808.
- 13 Verinata white paper. Analytical validation of the Verifi prenatal test. 2012.
- 14 ACOG Practice Bulletin 226. Aug 2020.

- 15 DiNonno et al. J Clin Med. 2019;8(9):1311.
- 16 Natera internal data on file.
- 17 Myriad Women's Health. Accessed October 23, 2019. https://myriadwomenshealth.com/
- 18 Progenity Innatal Clinician Guide. 2019. 19 Archibald et al. *Genet Med.* 2018;20:513-523. doi: 10.1038/
- gim.2017.134 20 Westemeyer et al. *Genet Med.* 2020;22(8):1320-1328. doi:
- Westemeyer et al. Genet Med. 2020;22(8):1320-1328. doi: 10.1038/s41436-020-0807-4
 Description of factor. National Description of a statement of a
- 21 Down syndrome facts. National Down Syndrome Society. Accessed December 2, 2020. https://www.ndss.org/aboutdown-syndrome/down-syndrome-facts/
- 22 ACOG Committee Opinion 690. March 2017.
- 23 ACOG Committee Opinion 691. March 2017. 24 Simon et al. *Fertil Steril.* 2018;110(1):113-121.
- 25 Spectrum PGT-M and PGT-A must be performed within one year of Horizon screening results. Promotional price is good for one test run and is not valid if patient chooses to file insurance. Shipping and batching fees apply. Restrictions apply. Both male and female must have completed a Horizon panel (Horizon 4, 14, 27, 106, 137, 274, or any other Horizon panels that include the four conditions on Horizon 4). Prior carrier screening or genetic
- testing identifying positive risk for a disorder voids special pricing. 26 Benn. *Clin Genet.* 2016;90(6):477-485.
- 27 Zhang et al. Nat Med. 2019;25(3):439-447
- 28 Toriello et al. Genet Med. 2008;10(6):457-60.
- 29 Shah et al. *Fertil Steril.* 2019;107(4):1028-1033. 30 Levy et al. *Obstet Gynecol.* 2014;123 (2 pt1):202-9.
- 31 Bell et al. Fertil Steril. 1999.71(2):334-41

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1.650.249.9090 | Fax 1.650.730.2272

The tests described have been developed and its performance characteristics determined by the CLIA-certified laboratory performing the tests. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2020 Natera, Inc. All Rights Reserved. NAT_WH_ProductBrochure_20201120_NAT-8020321

